

DISTRIBUTION OF SHARES BY SUBSTANTIAL SHAREHOLDER

MELBOURNE (AUSTRALIA) 4 December 2020: Invion Limited (ASX: IVX) (**Invion**) has been advised by Unlimited Innovation Group Limited (**UIG**), the company's largest shareholder holding 50.8% of Invion's shares, that UIG has completed an in-specie distribution of the Invion shares held by it to the members of UIG.

Invion has further been informed by UIG that, to ensure the distribution of shares by UIG to its members occurs in an orderly manner, the UIG members have agreed with UIG to enter into voluntary escrow arrangements ranging between 3 to 12 months, a summary of which is provided below.

Description	Escrow expiry	Quantity of securities	No. of holders
IVX 3 months escrow shares till 01/03/2021 (IVXESC0321)	01/03/2021	1,432,841,408	16 holders
IVX 6 months escrow shares till 01/06/2021 (IVXESC0621)	01/06/2021	1,160,779,413	32 holders
IVX 12 months escrow shares till 01/12/2021 (IVXESC1221)	01/12/2021	220,682,156	1 holder

Invion is not a party to the escrow arrangements but UIG has provided assurances to Invion's board that it will enforce these arrangements.

A current statement setting out the names of the 20 largest shareholders of fully paid ordinary shares and the percentage held by each is attached.

This announcement is authorised by the Board of Invion.				

Investor and Media enquiries:

Thian Chew (Chairman)

Brendon Lau (Investor & Media Relations)

T: +61 3 9692 7222

T: +61 409 341 613

E: <u>investor@inviongroup.com</u>
E: <u>brendon@vantagepointpartners.com.au</u>



INVION LIMITED

Top holders

Security: ORD.ASX [ORDINARY + ESCROW ORDINARY]

Top holders: 20

Rank	Name	A/C designation	02 Dec 2020	%IC
1	POLAR VENTURES LIMITED		545,217,721	9.86
2	NGPDT GREATER CHINA LIMITED		545,152,297	9.86
3	MR HONSUE CHO		284,626,482	5.15
4	ACSLNC PTY LTD	ACSLNC FAMILY	267,250,000	4.83
5	RMWC PTY LTD	RMWC FAMILY	220,682,156	3.99
6	YONG CHEN		200,000,000	3.62
7	BNP PARIBAS NOMINEES PTY LTD	<ib au="" drp="" noms="" retailclient=""></ib>	156,489,665	2.83
8	HONG DENG		141,739,597	2.56
9	SHENGLI WANG		136,288,074	2.46
10	GRAEME ERIC SCOTT		118,750,000	2.15
11	MING KIT HUI		96,666,667	1.75
12	RMWC PTY LTD	<rmwc a="" c="" family=""></rmwc>	93,865,000	1.70
13	SHUBO MIAO		73,333,333	1.33
14	SHENGWEI OU		66,666,667	1.21
14	MAK SIEW WEI		66,666,667	1.21
15	EQ INVESTMENT PTY LTD		62,500,000	1.13
16	PLATINUM HOMES LTD		62,333,333	1.13
17	SOO CORP PTY LTD		56,666,666	1.02
18	YINGHUA MA		54,000,000	0.98
19	HONGHUI CHEN		52,786,440	0.95
20	CITICORP NOMINEES PTY LIMITED		47,746,624	0.86
	Total		3,349,427,389	60.58
	Balance of register			39.42
		Grand total	5,529,042,295	100.00

About Invion

Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.